{"news_desk": "Editorial", "print_page": "26", "section_name": "Opinion", "subsection_name": null, "byline": {"original": "By THE EDITORIAL BOARD", "person": [], "organization": "THE EDITORIAL BOARD"}, "abstract": "Editorial criticizes proposed $160 billion merger of Pfizer and Allergan, saying it will allow combined company to evade American taxes; suggests deal should be illegal; warns that so-called corporate inversions will worsen trend in which corporate taxes as share of federal revenue have declined significantly; calls on Congress to pass law forbidding inversions.", "type_of_material": "Editorial", "word_count": "692", "lead_paragraph": "The $160 billion deal to combine Pfizer and Allergan does not appear to be illegal, but it should be.", "pub_date": "2015-11-24T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Pfizer\u2019s Big Breakthrough: Global Tax Avoidance", "content_kicker": "Editorial", "print_headline": "Pfizer\u2019s Big Tax Avoidance Play", "kicker": "Editorial"}, "snippet": "The $160 billion deal to combine Pfizer and Allergan does not appear to be illegal, but it should be.", "multimedia": [{"height": 126, "url": "images/2015/11/24/opinion/24tue1/24tue1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/11/24/opinion/24tue1/24tue1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 743, "url": "images/2015/11/24/opinion/24tue1/24tue1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "743", "xlarge": "images/2015/11/24/opinion/24tue1/24tue1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/11/24/opinion/24tue1/24tue1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/11/24/opinion/24tue1/24tue1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/11/24/opinion/pfizers-big-breakthrough-global-tax-avoidance.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Editorials", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Allergan Inc", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Tax Shelters", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Relocation of Business", "name": "subject"}, {"rank": "7", "is_major": "Y", "value": "Corporate Taxes", "name": "subject"}], "blog": [], "_id": "56541dff38f0d858aca89d18", "source": "The New York Times"}